Karyopharm Therapeutics | KPTI - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 58.94B 4.03B 2025-12
Abbott USD 29.64B 19.74B 2026-03
Amgen USD 51.89B 1.88B 2026-03
AstraZeneca USD 25.96B 177M 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Enanta Pharmaceuticals USD 0 0 2024-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
Incyte USD 29.41M 785K 2026-03
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
MacroGenics USD 68.71M 1.29M 2026-03
Merck USD 46.67B 77M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Novartis USD 37.45B 7.86B 2026-03
Novartis USD 37.45B 7.86B 2026-03
Pfizer USD 60.57B 1.08B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 25.22B 2.21B 2026-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.37T 99.51B 2026-03
Tectonic Therapeutic USD 17K 26K 2026-03
TG Therapeutics USD 745.14M 499.5M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Xencor USD 82.12M 5.64M 2026-03